Site-specific delivery of iloprost during experimental angioplasty suppresses smooth muscle cell proliferation

Journal of Vascular and Interventional Radiology

Volumn 9, Issue 3, 1998, Pages 487-493

  Kandarpa, Krishna ^a   Nakatsuka, Seishi ^b   Yousuf, Naveed ^a   Barry, James J ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

^c BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Angioplasty experimental; Arteries, transluminal angioplasty; Drugs, effects; Iloprost; Smooth muscle cells

Indexed keywords

CYCLINE; ILOPROST; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; HYDROGEL; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS; SWINE;

EID: 0031832002     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(98)70305-7     Document Type: Article

References (33)

1. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995; 25:516-520.
2. Berk B, Harris K. Restenosis after percutaneous transluminal coronary angioplasty: new therapeutic insights from pathogenic mechanisms. Advances in internal medicine. St. Louis: Mosby-Year Book, 1995; 445-501.
3. Phillips-Hughes J, Kandarpa K. Restenosis: pathophysiology and preventive strategies. JVIR 1996; 7:321-333.
4. Gibbons GH, Dzau VJ. Emerging concepts of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
5. Shi Y, Pieniek M, Fard A, et al. Adventitial remodeling after coronary arterial injury. Circulation 1996; 93:340-348.
6. Isner J. Vascular remodeling: Honey, I think I shrunk the artery. Circulation 1994; 90:2937-2941.
7. Dzau VJ, Gibbons GH, Cooke JP, Omoigui N. Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives. Circulation 1993; 87:705-719.
8. Carter AJ, Laird JR, Farb A, et al. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 1994; 24:1398-1405.
9. Simons M, Leclerc G, Safian RD, et al. Relation between activated smooth muscle cells in coronary artery lesions and restenosis after atherectomy. N Engl J Med 1993; 328:608-613.
10. O'Brien ER, Alpers CE, Steward DK, et al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res 1993; 73:223-231.
11. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993; 91:1469-1480.
12. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57:105-112.
13. Libby P, Sukhova G, Grogi E, et al. Restenosis as an example of vascular hyperplastic disease: reassessment of potential mechanisms. Advances in vascular surgery. St. Louis: Mosby-Year Book, 1995:279-290.
14. Herrman JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (Part 1). Drugs 1993; 46:18-52.
15. Herrman JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (Part II). Drugs 1993; 46:249-262.
16. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis fact, fancy, and future. Circulation 1994; 90:2070-2084.
17. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol 1994; 23:1234-1244.
18. Kandarpa K, Nakatsuka S, Bravo S, Harapanhalli R, Barry JJ. Mural delivery of iloprost with use of hydrogel-coated balloon catheters suppresses local platelet aggregation. JVIR 1997; 8:997-1004.
19. Darius H, Hossmann V, Schror K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. Klin Wochenbschr 1986; 64:545-551.
20. Azrin MA, Mitchel JF, Fram DB, et al. Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation 1994; 90:433-441.
21. Feletou M, Teisseire B. Vascular pharmacology of the micropig: importance of the endothelium. In: Swindle MM, Moody DC, Phillips LD, eds. Swine as models in biomedical research. Ames: Iowa State University, 1992; 74-95.
22. Schwartz RS, Murphy JG, Edwards WD, et al. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990; 82:2190-2200.
23. Heras M, Chesebro JH, Penny WJ, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78:654-660.
24. Zeymer U, Fishbein MC, Forrester JS, Cercek B. Proliferating cell nuclear antigen immunohistochemistry in rat aorta after balloon denudation: comparison with thymidine and bromodeoxyuridine labeling. Am J Pathol 1992; 141:685-690.
25. Fram DB, Artez T, Azrin MA, et al. Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J Am Coll Cardiol 1994; 23:1570-1577.
26. Nunes GL, Hanson SR, King SB III, Sahatjian RA, Scoot NA. Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. J Am Coll Cardiol 1994; 23:1578-1583.
27. Mitchel JF, Azrin MA, Fram DB, et al. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. Circulation 1994; 90:1979-1988.
28. Belch JJ, Greer I, McLaren M, et al. The effects of intravenous ZK36-374, a stable prostacyclin analogue, in normal volunteers. Prostaglandins 1984; 28:67-77.
29. Krause W, Kraise T. Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. Eur J Clin Pharmacol 1987; 32:597-605.
30. Rucker W, Schror K. Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue. Biochemical Pharmacology 1983; 32:2405-2410.
31. Iacoviello L, De Curtis A, D'Adamo MC, et al. Prostacyclin is required for t-PA release after venous occlusion. Am J Physiol 1994; 266:H429-434.
32. Sarembock IJ, LaVeau PJ, Sigal SL, et al. Influence of inflation pressure and balloon size on the development of intimai hyperplasia after balloon angioplasty: a study in the atherosclerotic rabbit. Circulation 1989; 80:1029-1040.
33. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horse radish peroxidase. Atherosclerosis 1987; 65:215-225.